Atypical Presentation of Halo Nevus over Eyelid with Poliosis: A Dermatoscopic Perspective.

Halo nevus (HN) is benign skin condition with a central melanocytic nevus, surrounded by an area or halo of depigmentation. It is the result of immunological response of the body toward the nevus, which destroys the melanocytes in surrounding skin, leading to the depigmented halo. An increased frequency of HN in patients with vitiligo is observed. It is more commonly seen in children or young adults of either sex, particularly on the trunk, less commonly on the face, neck, and limbs. We present a rare case of HN which was present on the lower eyelid associated with poliosis, diagnosed with dermatoscopy.

Direct Unsupervised Super-Resolution Using Generative Adversarial Network (DUS-GAN) for Real-World Data.

The deep learning models for the Single Image Super-Resolution (SISR) task have found success in recent years. However, one of the prime limitations of existing deep learning-based SISR approaches is that they need supervised training. Specifically, the Low-Resolution (LR) images are obtained through known degradation (for instance, bicubic downsampling) from the High-Resolution (HR) images to provide supervised data as an LR-HR pair. Such training results in a domain shift of learnt models when real-world data is provided with multiple degradation factors not present in the training set. To address this challenge, we propose an unsupervised approach for the SISR task using Generative Adversarial Network (GAN), which we refer to hereafter as DUS-GAN. The novel design of the proposed method accomplishes the SR task without degradation estimation of real-world LR data. In addition, a new human perception-based quality assessment loss, i.e., Mean Opinion Score (MOS), has also been introduced to boost the perceptual quality of SR results. The pertinence of the proposed method is validated with numerous experiments on different reference-based (i.e., NTIRE Real-world SR Challenge validation dataset) and no-reference based (i.e., NTIRE Real-world SR Challenge Track-1 and Track-2) testing datasets. The experimental analysis demonstrates committed improvement from the proposed method over the other state-of-the-art unsupervised SR approaches, both in terms of subjective and quantitative evaluations on different reference metrics (i.e., LPIPS, PI-RMSE graph) and no-reference quality measures such as NIQE, BRISQUE and PIQE. We also provide the implementation of the proposed approach (https://github.com/kalpeshjp89/DUSGAN) to support reproducible research.

Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis.

BACKGROUND AND OBJECTIVES: To report safety of ocrelizumab (OCR) up to 7 years in patients with relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) enrolled in clinical trials or treated in real-world postmarketing settings. METHODS: Safety analyses are based on integrated clinical and laboratory data for all patients who received OCR in 11 clinical trials, including the controlled treatment and open-label extension (OLE) periods of the phase 2 and 3 trials, plus the phase 3b trials VELOCE, CHORDS, CASTING, OBOE, ENSEMBLE, CONSONANCE, and LIBERTO. For selected adverse events (AEs), additional postmarketing data were used. Incidence rates of serious infections (SIs) and malignancies were contextualized using multiple epidemiologic sources. RESULTS: At data cutoff (January 2020), 5,680 patients with multiple sclerosis (MS) received OCR (18,218 patient-years [PY] of exposure) in clinical trials. Rates per 100 PY (95% confidence interval) of AEs (248; 246-251), serious AEs (7.3; 7.0-7.7), infusion-related reactions (25.9; 25.1-26.6), and infections (76.2; 74.9-77.4) were similar to those within the controlled treatment period of the phase 3 trials. Rates of the most common serious AEs, including SIs (2.01; 1.81-2.23) and malignancies (0.46; 0.37-0.57), were consistent with the ranges reported in epidemiologic data. DISCUSSION: Continuous administration of OCR for up to 7 years in clinical trials, as well as its broader use for more than 3 years in the real-world setting, are associated with a favorable and manageable safety profile, without emerging safety concerns, in a heterogeneous MS population. CLASSIFICATION OF EVIDENCE: This analysis provides Class III evidence that long-term, continuous treatment with OCR has a consistent and favorable safety profile in patients with RMS and PPMS. This study is rated Class III because of the use of OLE data and historical controls.